1.Dysbacteriosis caused by antibiotics, and its prevention and cure
Chuanke DUAN ; Daoping JIANG ; Yushen WANG
Chinese Pharmacological Bulletin 1998;0(S1):-
There are many etiologies, which can produce dysbacteriosis. Among these etiologies which have serious influence and are commone clinically is prolonged, large and abuse of antibiotics.The principles of prevention and cure for dysbacteriosis are presented as follows: A. Reason-able use of antibiotics: (1) Short-term treatment with small dose; (2) Whenver possible, using nar-rowspectrum and different broadsprectram antibiotics ; ( 3 ) Avoiding taking orally; ( 4 ) Selective decontamination. B. Recommending usage of bio-gen and its growth factors.
2.Treatment of velopharyngeal insufficiency with a modified pharyngngeal flap
Guomin WANG ; Yushen YANG ; Liping JIANG ; Yousheng TANG ; Longhao YAO
Journal of Practical Stomatology 2000;0(06):-
Objective:To study the a feasibility of modified pharyngoplasty in the treatment of velopharyngeal insufficiency.Methods:30 cases of velopharyngeal insufficiency were treated with a modified pharyngoplasty followed by speech training.The effects of the treatment were evaluated by blowing test (BT),chinese articulation inteligibility test (CIT) and hypernasality observation(HO).Results:Before and after treatment BT was 1~26 and 8~40,CIT(%) 20~60 and 47~82,HO(cases) 30 and 3,respectively.Conclusions:The modified pharyngoplastic surgery is feasible in the treatment of velophayngeal insufficiency.
3. Genetic analysis of an adult with mosaicism of uniparental disomy 11p
Yalan XIN ; Hui FANG ; Penghui YUAN ; Yushen JIANG
Chinese Journal of Medical Genetics 2019;36(12):1219-1221
Objective:
To analyze the clinical phenotype and genomic abnormality of an adult featuring congenital heart defect and multiple developmental disorders.
Methods:
The patient was subjected to conventional G-banding chromosomal karyotyping and single nucleotide polymorphism microarray (SNP-array) analysis.
Results:
The patient showed a normal karyotype, while SNP-array revealed a 42.7 Mb mosaic uniparental disomy (UPD) in the 11p15.5p12 region ([hg19] chr11: 491 333 - 43 189 376).
Conclusion
The mosaicism of UPD of 11p15.5p12 region probably underlies the congenital heart defect and developmental disorders in the patient.
4.Efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with advanced hepatocellular carcinoma
Long CHENG ; Yue ZHANG ; Yushen LIU ; Zhaoqing DU ; Zhaoyang GUO ; Yangwei FAN ; Ting LI ; Xu GAO ; Enrui XIE ; Zixuan XING ; Wenhua WU ; Yinying WU ; Mingbo YANG ; Jie LI ; Yu ZHANG ; Wen KANG ; Wenjun WANG ; Fanpu JI ; Jiang GUO ; Ning GAO
Journal of Clinical Hepatology 2024;40(10):2034-2041
ObjectiveTo investigate the efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with unresectable or advanced hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for the patients with unresectable/advanced HCC who attended six hospitals from January 1, 2019 to March 31, 2021, and all patients received camrelizumab monoclonal antibody treatment, among whom 84.8% also received targeted therapy. According to the age of the patients, they were divided into elderly group (≥65 years) and non-elderly group (<65 years). The two groups were assessed in terms of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and immune-related adverse events (irAE). The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups; the independent samples t-test was used for comparison of normally distributed continuous data, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional hazards regression analyses were used to determine the independent influencing factors for PFS and DCR at 6 months. ResultsA total of 99 HCC patients were enrolled, with 27 in the elderly group and 72 in the non-elderly group. The elderly group had an OS rate of 67.8%, an ORR of 44.4%, and a DCR of 74.1% at 12 months and a median PFS of 6.4 (95% confidence interval [CI]: 3.0 — 12.4) months, with no significant differences compared with the non-elderly group (all P>0.05). The median OS was unavailable for the elderly group, while the non-elderly group had an OS of 18.9 (95%CI: 13.0 — 24.8) months; there was no significant difference between the two groups (P=0.485). The univariate and multivariate Cox regression analyses showed that major vascular invasion (MVI) was an independent risk factor for PFS (hazard ratio [HR]=2.603, 95%CI: 1.136 — 5.964, P=0.024) and DCR (HR=3.963, 95%CI: 1.671 — 9.397, P=0.002) at 6 months, while age, sex, etiology of HBV infection, presence of extrahepatic metastasis, Child-Pugh class B, and alpha-fetoprotein>400 ng/mL were not associated with PFS or DCR at 6 months. For the elderly group, the incidence rates of any irAE and grade 3/4 irAE were 51.9% and 25.9%, respectively, with no significant differences compared with the non-elderly group (P>0.05), and skin disease was the most common irAE in both groups (39.4%). ConclusionCamrelizumab monoclonal antibody combined with molecular-targeted therapy has similar efficacy and safety in patients with unresectable/advanced HCC aged ≥65 years and those aged <65 years. MVI is associated with suboptimal response to immunotherapy and poor prognosis.
5.Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
Guobing LIU ; Weihai ZHUO ; Yushen GU ; Zhi YANG ; Yue CHEN ; Wei FAN ; Jianming GUO ; Jian TAN ; Xiaohua ZHU ; Li HUO ; Xiaoli LAN ; Biao LI ; Weibing MIAO ; Shaoli SONG ; Hao XU ; Rong TIAN ; Quanyong LUO ; Feng WANG ; Xuemei WANG ; Aimin YANG ; Dong DAI ; Zhiyong DENG ; Jinhua ZHAO ; Xiaoliang CHEN ; Yan FAN ; Zairong GAO ; Xingmin HAN ; Ningyi JIANG ; Anren KUANG ; Yansong LIN ; Fugeng LIU ; Cen LOU ; Xinhui SU ; Lijun TANG ; Hui WANG ; Xinlu WANG ; Fuzhou YANG ; Hui YANG ; Xinming ZHAO ; Bo YANG ; Xiaodong HUANG ; Jiliang CHEN ; Sijin LI ; Jing WANG ; Yaming LI ; Hongcheng SHI
Chinese Journal of Clinical Medicine 2024;31(5):844-850
177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.